PARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of Olaparib to Platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients
Drewett, L. Pinilla, K. A. Grybowicz, L. Wulff, J. Dayimu, A. Demiris, N. Lucey, R. Vallier, A. L. Qian, W. D. Machin, A.
Drewett, L.
Pinilla, K. A.
Grybowicz, L.
Wulff, J.
Dayimu, A.
Demiris, N.
Lucey, R.
Vallier, A. L.
Qian, W. D.
Machin, A.
Citations
Altmetric:
Abstract
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Drewett L, Pinilla KA, Grybowicz L, Wulff J, Dayimu A, Demiris N, et al. Randomized, double-blind, phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1-positive metastatic NSCLC. Cancer Research. 2022 Jun;82(12). PubMed PMID: WOS:000892509500082.